A New JAAD Paper Calls T-Cells a Biomarker for Hair Loss That Older Studies Used to Rule It Out

A paper posted online September 6, 2026 in the Journal of the American Academy of Dermatology proposes T-cells as a candidate biomarker for female pattern hair loss, according to the listing from Elsevier and the AAJD (Marrero Berrios, Encarnacion, Desir, Prasad, Hedberg, Taylor and Seykora). The full text sits behind a paywall, so the claim can currently be evaluated only at the level of its framing, not its data.

That framing runs against a long-standing classification. Female pattern hair loss has typically been treated as a non-inflammatory condition, in contrast to alopecia areata, which is defined by T-cell-mediated autoimmune attack on the follicle. Histology from the Whiting era already documented a mild perifollicular lymphohistiocytic infiltrate in roughly 73% of pattern hair loss biopsies, but that finding was folded into a separate category called microinflammation rather than treated as diagnostic.

The sharper tension sits in a 2015 JAAD paper that used CD3+ T-cell presence within the follicular stelae as a histopathologic feature that distinguishes diffuse alopecia areata from pattern hair loss. In that earlier framework, finding T-cells around a follicle pointed away from a female pattern hair loss diagnosis. A 2026 paper naming T-cells as a marker for the same condition would need to explain how it reconciles with, or narrows, that differential-diagnosis logic, and the abstract available online does not do that work.

A related study in the Journal of Investigative Dermatology, a pilot comparative transcriptomic analysis matching vertex and occipital scalp tissue (PMID 41453597), reported CD4+ T-cell infiltration at the follicular bulge correlated with hair-cycle disruption, alongside cytotoxic CD8+ T-cell and aberrant B-cell activation signatures. Whether the JAAD paper draws on that dataset, extends it, or represents an independent group is not resolved by the listing alone, and the author lists do not visibly overlap.

The practical stakes of the word biomarker also depend on details the abstract does not supply. Current diagnosis of female pattern hair loss relies on clinical exam, with sensitivity near 77% and specificity near 72% against biopsy, or on invasive tissue sampling reserved for ambiguous cases. A T-cell signature drawn from blood would represent a screening tool; a T-cell signature drawn from scalp biopsy would mostly formalize a category clinicians already inspect under the microscope. Until the paper is read past the abstract, that distinction, and the sample size behind it, remains the open question the headline leaves unanswered.